Friday, 24 Jan 2020

You are here

Initiation of Urate-Lowering Therapy During Gout Attacks

A retrospective analysis examined whether it's better to initiate urate-lowering therapy (ULT) during or after an attack of acute gout.

Patients on ULT for > 3yrs were divided into 2 groups: 1) group 1 included 123 patients who started ULT during an acute attack of gout; and 2) group 2 included 457 patients who were given ULT after an acute attack. Both groups had similar mean serum urate levels at the start (7.8±1.4mg/dL vs. 7.9±1.9mg/dL, respectively) and both equally achieved a uric acid target level of <6.0mg/dL (66.7 and 65.6%, respectively).

The time to achieve target SUA levels was shorter in group 1 than in group 2, but the number of flares were higher in group 1 compared to those in group 2. Chronic kidney disease was lower in group 1 than in group 2. Although initiation of ULT during the acute gouty attack decreased the time required to reach the target urate levels and the incidence of chronic kidney disease, but the attack rate was greater in the first 12 weeks.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Diabetics using SGLT2 Inhibitors have a lower Gout Risk

Researchers from the Brigham and Women's Hospital have reported that adults with type 2 diabetes who were treated with SGLT2 inhibitors had a lower risk of gout compared to GLP1 agonist, suggesting that sodium–glucose cotransporter-2 inhibitors may reduce the risk for gout with type 2 diabetes mellitus (T2DM).

A Role for SGLT2 Inhibition in Gout?

The antidiabetic medication canagliflozin (Invokana) lowered serum urate and reduced the risk of gout flare in a post-hoc analysis of data from two large clinical trials.

Predicting Inpatient Gout Flares

Analysis of New Zealand hospitalized patients revals nine predictors of inpatient flare for people with comorbid gout.

This retrospective cohort study of hospitalised patients with comorbid gout included 625 hospitalised patients, 87 experienced inpatient gout flare.

There were 9 predictors of an inpatient gout flare:

Pegradicase+ImmTOR SEL-212 Shows Promising Results In Active Gout

Therapies targeting sUA accumulation or improving its excretion are widely used for treatment of symptoms and prevention of progression of gout for decades. Despite our best effort, there is still a significant amount of patients who remain symptomatic and/or experiences progressive joint damage and disability. Regardless of the cause, either its lack of compliance or poor tolerability, more effective treatments are needed.

PANLAR Ultrasound Study Group: Recommendations On Imaging Modalities In Gout

Gout is a systemic inflammatory disease with high potential for joint damage due to erosive changes and MSU deposits resulting in disability and chronic pain. Prompt diagnosis and effective treatment are key to better long term outcomes and decreased disability.